TERESA KARCSMAR: Open Payments
NPI 1134312200 · WINTER GARDEN, FL. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$763 in 28 payments from 18 companies in 2025. Trend: 2023 $1,461 · 2024 $1,254 · 2025 $763
Food & beverage: $763
| Company | Payments | Amount |
|---|---|---|
| AstraZeneca Pharmaceuticals LP | 3 | $164 |
| Takeda Pharmaceuticals U.S.A., Inc. | 3 | $87 |
| JAZZ PHARMACEUTICALS INC. | 2 | $70 |
| Novo Nordisk Inc | 2 | $48 |
| Avadel CNS Pharmaceuticals, LLC | 1 | $36 |
| Lilly USA, LLC | 2 | $34 |
| GENZYME CORPORATION | 1 | $33 |
| Bayer Healthcare Pharmaceuticals Inc. | 2 | $33 |
| Amgen Inc. | 2 | $32 |
| Baxter Healthcare | 1 | $31 |
Products named: FARXIGA, GLASSIA, XYWAV, Ozempic, LUMRYZ, MOUNJARO, DUPIXENT, Kerendia.
Industry payments across FL — which companies pay providers there.
